-
-
-
-
-
-
-
Nektar Therapeutics (NKTR) PT Raised to $115 at Oppenheimer
-
-
-
-
-
-
-
Nektar Therapeutics (NKTR) on Watch Following M&A Chatter
-
-
-
-
-
-
-
Nektar Therapeutics (NKTR) Misses Q2 EPS by 258c
-
-
-
-
-
-
-
Nektar Therapeutics (NKTR) PT Raised to $69 at Jefferies, 'data update gives us further confidence in Rezpeg's potential'
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Nektar Therapeutics (NKTR)
-
-
-
-
-
-
-
Nektar Therapeutics (NKTR) PT Lowered to $1 at Jefferies
-
-
-
-
-
-
-
Nektar Therapeutics (NKTR) competes target enrollment in its REZOLVE-AD Phase 2b study
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

